Numerous studies show that single doses may be insufficient because of an individual’s weight, or the severity of the ...
MannKind Corporation drives 2026 momentum via Afrezza and FUROSCIX; label updates and execution risks define pharma ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果